Advertisement Amylin, Alkermes announce availability of Bydureon in US - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Amylin, Alkermes announce availability of Bydureon in US

Amylin Pharmaceuticals and Alkermes have announced the availability of Bydureon (exenatide extended-release for injectable suspension) by prescription in the US pharmacies.

Bydureon, once-weekly treatment for type 2 diabetes, was approved by FDA as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

The approval was based on safety and efficacy data from the DURATION clinical trial program, in which treatment with Bydureon resulted in improvements in glycemic control in a once-weekly dose.

Bydureon is provided in a straightforward single-dose tray so that patients can self-administer the once-weekly subcutaneous (under the skin) injection, the companies said.